Share on StockTwits
 

OraSure Technologies (NASDAQ:OSUR)‘s stock had its “buy” rating reaffirmed by equities researchers at Jefferies Group in a research report issued on Friday, American Banking and Market News reports. They currently have a $9.00 price objective on the stock. Jefferies Group’s target price would indicate a potential upside of 38.04% from the stock’s previous close.

OraSure Technologies (NASDAQ:OSUR) traded down 4.54% during mid-day trading on Friday, hitting $6.52. The stock had a trading volume of 703,423 shares. OraSure Technologies has a 1-year low of $3.75 and a 1-year high of $7.42. The stock has a 50-day moving average of $6.15 and a 200-day moving average of $5.64. The company’s market cap is $362.5 million.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, November 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.07. The company had revenue of $24.70 million for the quarter, compared to the consensus estimate of $24.21 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. The company’s quarterly revenue was up 11.8% on a year-over-year basis. On average, analysts predict that OraSure Technologies will post $-0.40 earnings per share for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Cowen and Company cut their price target on shares of OraSure Technologies from $8.00 to $7.00 in a research note to investors on Tuesday, November 26th. Finally, analysts at Stephens downgraded shares of OraSure Technologies from an “overweight” rating to an “equal weight” rating in a research note to investors on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $7.92.

OraSure Technologies, Inc, is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company’s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.